{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022218","form_type":"8-K","ticker":"BLFS","cik":"0000834365","company_name":"BIOLIFE SOLUTIONS INC","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.110701+00:00","generated_at":"2026-06-02T07:49:15.509380+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioLife Q1 net loss $10.2M; revenue down 16% YoY; divests GCI freezer unit, reaffirms 2024 guidance","bullets":["Q1 total revenue $31.7M (-16% YoY); Cell Processing $16.2M (+10% seq), Biostorage $7.1M (+25% YoY), Freezers $8.4M (-35% YoY).","GAAP net loss $10.2M ($0.22 loss per share); adjusted EBITDA -$1.2M; pro forma ex-GCI adj. EBITDA +$3.6M (13% of revenue).","Closed sale of GCI freezer business Apr 17; funded $4.9M cash into GCI and repaid $2.6M debt to facilitate transaction.","Affirms FY24 revenue guidance $95.5M-$100.0M (ex-freezers); expects full-year positive adjusted EBITDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022218","json":"https://secwatch.observer/filing/0001628280-24-022218.json","markdown":"https://secwatch.observer/filing/0001628280-24-022218.md","text":"https://secwatch.observer/filing/0001628280-24-022218.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/834365/000162828024022218/0001628280-24-022218-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/834365/000162828024022218/blfs-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:49:15.509380+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"480a4a46401c9cf42528ebc1b33ca4f13a317707","claim":"BIOLIFE SOLUTIONS INC reported first quarter ended March 31, 2024 results: revenue $31.7 million, net income $10.2 million, EPS $0.22. Guidance reaffirmed.","evidence_excerpt":"51 % Adjusted Gross Margin 53 % Net Loss $ (4,453) Adjusted EBITDA $ 3,583 Adjusted EBITDA as a % of Revenue 13 % REVENUE • Total revenue for the first quarter of 2024 was $31.7 million, a decrease of $6.0 million, or 16%, from $37.7 million for the first quarter of 2023 and down $1.0 million, or 3%, sequentially from the fourth quarter of 2023. ◦ Cell","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/834365/000162828024022218/0001628280-24-022218-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$31.7 million"},{"label":"Net income","value":"$10.2 million"},{"label":"EPS","value":"$0.22"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}